Larimar Therapeutics Announces Formation of Scientific Advisory Board
“Larimar is privileged to have this group of prestigious, multidisciplinary advisors who are committed to advancing the research and development of CTI-1601 for Friedreich’s ataxia,” said
The members of Larimar’s
Russell (Rusty) Clayton, DO – Dr. Claytonwill serve as the Scientific Advisory Board Chair for Larimar Therapeutics. He brings more than 15 years of executive experience in pharmaceutical, biologics and medical device development and commercialization as a consultant in clinical development, medical affairs and regulatory affairs. Prior to becoming a consultant, Dr. Claytonwas the chief medical officer at Alcresta Therapeutics, a medical device company. Prior to Alcresta Therapeutics, he was the senior vice president of research and development at Discovery Labs, a pharmaceutical and medical device company, where he led the scientific and regulatory efforts leading to the marketing authorization of Discovery’s first product. Dr. Claytonis a board-certified pediatric pulmonologist who practiced at St. Christopher’s Hospital for Childrenand the Children’s Hospital of Philadelphiaprior to beginning his career in the pharmaceutical, biologics, and medical device industry. He received his DO from the Philadelphia College of Osteopathic Medicine.
- Marni J. Falk, MD –
Dr. Falkis Executive Director of the Mitochondrial Medicine Frontier Program at The Children’s Hospital of Philadelphia(CHOP) and Professor in the Division of Human Genetics, Department of Pediatricsat University of Pennsylvania Perelman School of Medicine. She also serves as a principal investigator of a National Institutes of Health, pharma and philanthropic-funded translational laboratory group at CHOP that investigates the causes and global metabolic consequences of mitochondrial disease and directs multiple clinical treatment trials in mitochondrial disease patients. Dr. Falkreceived her BS in biology and MD from the George Washington University School of Medicine. In addition, she completed dual specialty training in the Pediatrics and Clinical Genetics residency program at Case Western Reserve University. Giovanni Manfredi, MD, PhD – Dr. Manfrediis the Finbar and Marianne Kenny Professorin Clinical and Research Neurology at Weill Cornell Medicine. He is also a Professor of Neuroscience and directs the graduate program in Neuroscience at Weill Cornell Medicine. Dr. Manfredi’s lab studies alterations of mitochondrial metabolism in neurodegenerative diseases, particularly amyotrophic lateral sclerosis and primary inherited mitochondrial encephalomyopathies. Dr. Manfredihas authored more than 100 publications focused in areas including neurodegenerative and mitochondrial diseases. Dr. Manfredireceived his MD and PhD in anatomy and cell biology from Catholic Universityof the Sacred Heart in Rome, where he also completed a residency in neurology. Mark Payne, MD – Dr. Payneis a renowned scientist and practicing cardiovascular physician who brings a long-standing scientific focus on protein targeting to mitochondria and a dedication to treating cardiomyopathies of childhood, including Friedreich’s ataxia. He is the inventor of the original therapy for frataxin protein replacement in Friedreich’s ataxia and co-founded Chondrial Therapeutics, which became Larimar Therapeutics, Inc.He holds multiple patents on mitochondrial biology and repair. He is a tenured professor of pediatrics at Indiana University School of Medicinewhere he directs multiple NIH-funded training, clinical, and research programs as a principal investigator. Dr. Paynereceived his BS in natural sciences from Washington & Lee University, and his MD from the University of Texasat Houston. He performed his postdoctoral clinical and research training at Washington University in St. Louis. He is a Fellow of the American College of Cardiologyand the American Academy of Pediatrics. MarshallSummar, MD – Dr. Summarserves as Chief of the Division of Genetics and Metabolism, Director of the Rare Disease Instituteand is the Margaret O'Malley Chair of Genetic Medicine at Children’s National Hospital. In addition to guiding clinical research and treatment, he developed and launched the world’s first Rare Disease Institute(RDI) at Children’s. The RDI is the first Clinical Center of Excellencedesignated by the National Organization for Rare Diseases(NORD) and focuses on building best clinical practices and diagnostic pathways for patients. With NORD and the FDA, Dr. Summarhas worked to develop a patient-driven natural history platform employed by over 35 rare disease advocacy organizations. He received his BS in molecular biology from Vanderbilt Universityand his MD from University of Tennessee Center for Health Sciences.
Source: Larimar Therapeutics, Inc.